Crinetics Pharmaceuticals, Inc. 8-K

What Happened
Crinetics Pharmaceuticals (CRNX) filed an 8-K on April 10, 2026 announcing that Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026. The company and Mr. Knight entered an Independent Consultant Agreement effective April 10, 2026, under which he will provide operational and clinical development services through April 10, 2027 (with a possible six‑month extension by mutual written agreement). The 8-K was signed by President and CEO R. Scott Struthers.

Key Details

• Resignation effective date: April 10, 2026.
• Consulting term: April 10, 2026 to April 10, 2027; may be renewed for an additional six months by mutual written consent.
• Compensation: $400 per hour, capped at 20 hours per month (maximum ~$8,000/month), plus reimbursement for pre‑approved travel and out-of-pocket expenses.
• Equity and option effects: Unvested restricted stock units and stock options forfeited on the resignation date; vested stock options remain exercisable until three months after the end of the consulting period (or earlier if the consulting period is terminated for cause).
• Other terms: Mr. Knight agreed to a general release of claims related to his departure, and the company agreed to extend certain indemnification rights during the consulting period.

Why It Matters
This filing documents an executive transition in Crinetics’ clinical and operations leadership while providing for short‑term continuity via a limited consulting arrangement. The consulting agreement caps company cash exposure (hourly fee and limited hours) and sets clear timelines for Mr. Knight’s involvement. For investors, important takeaways are the limited duration and scope of the consulting role, the forfeiture of unvested equity (which affects Mr. Knight’s future ownership stake), and the exercisability window for vested options. The arrangement may help smooth near‑term clinical and operational activities, but it also confirms a change in permanent leadership for development and operations.